Alcon Inc. (ALC)
$
90.12
+1.99 (2.21%)
Key metrics
Financial statements
Free cash flow per share
3.2607
Market cap
44.6 Billion
Price to sales ratio
4.4910
Debt to equity
0.2361
Current ratio
2.7012
Income quality
1.8827
Average inventory
2.3 Billion
ROE
0.0522
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The financial data pertains to the fiscal year 2024. During this period, the company incurred an income tax expense of $238,000,000.00 indicating its tax obligations. The net total of other income and expenses is -$157,000,000.00 reflecting non-core financial activities. Furthermore, the gross profit ratio is 0.56 reflecting the efficiency of the company's production and sales operations. The net income ratio is 0.10 reflecting the company's profitability margin. Alcon Inc. is dedicated to advancing eye care through its Surgical and Vision Care segments, offering a comprehensive range of products such as intraocular lenses, surgical equipment, diagnostic tools, contact lenses, and ocular health solutions. Founded in 1945 and headquartered in Geneva, Switzerland, Alcon is committed to innovation and quality, ensuring that healthcare professionals and patients benefit from its advanced technologies and eye care solutions. The stock is reasonably priced at $87.32 appealing to a broad range of investors. With a mid-range market capitalization of $44,573,352,000.00 the company is a steady performer. Additionally, the stock has an average trading volume of 1,671,156.00 indicating moderate liquidity. Alcon Inc. is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth. The company’s strategic focus on enhancing vision care and developing advanced surgical solutions positions it as a vital contributor in the eye care market, meeting the diverse needs of eye care professionals and patients worldwide.
Is Alcon Inc. (ALC) a good investment?
Investing in Alcon Inc. (ALC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Alcon Inc. (ALC)'s stock forecast?
Analysts predict Alcon Inc. stock to fluctuate between $80.48 (low) and $101.10 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alcon Inc.'s market capitalization?
As of 2025-08-20, Alcon Inc.'s market cap is $44,573,352,000, based on 494,600,000 outstanding shares.
How does Alcon Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alcon Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Alcon Inc. pay dividends?
Alcon Inc. pays dividends. The current dividend yield is 0.36%, with a payout of $0.33 per share.
How can I buy Alcon Inc. (ALC) stock?
To buy Alcon Inc. (ALC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALC. Place an order (Market, Limit, etc.).
What is the best time to invest in Alcon Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alcon Inc. perform in the last earnings report?
Revenue: $9,911,000,000 | EPS: $2.06 | Growth: 4.04%.
Where can I find Alcon Inc.'s investor relations reports?
Visit https://www.alcon.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alcon Inc.?
You can explore historical data from here
What is the all-time high and low for Alcon Inc. stock?
All-time high: $101.10 (2024-09-12) | All-time low: $55.21 (2022-10-13).
What are the key trends affecting Alcon Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Alcon remains a leader in eye care, benefiting from strong market positioning and long-term industry tailwinds like aging populations and technological advances. Recent M&A activity, including the STAAR Surgical acquisition, enhances long-term growth but pressures near-term earnings and raises valuation concerns. Despite solid sales growth and manageable debt, shares trade at a demanding 29-30x earnings multiple, which I view as fully valued given current growth rates.
benzinga.com
U.S. stock futures were slightly lower this morning, with the S&P 500 futures falling around 0.1% on Wednesday.
wsj.com
The company said it expects a $100 million hit from tariffs this year.
zacks.com
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
businesswire.com
GENEVA--(BUSINESS WIRE)--Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical.
businesswire.com
AHMEDABAD, India--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a strong presence at the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. APACRS will be held at Mahatma Mandir Convention and Exhibition Centre (MMCEC) in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on exper.
globenewswire.com
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breached their fiduciary duties in connection with the proposed sale of the Company to Alcon (NYSE: ALC).
zacks.com
ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.
businesswire.com
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. “Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who help.
zacks.com
ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.
See all news
